Voronoi Adds Malaysia NPRA Approval Application for VRN110755 Phase 1/2 Trial with No Shareholder Value Impact
Voronoi disclosed a correction to its clinical trial plan change application for VRN110755 Phase 1/2, adding that the submission to Malaysia's NPRA has been completed.
This correction expands the list of regulatory authorities to include Malaysia, reflecting global expansion of the trial.
After confirming safety and early efficacy signals in Phase 1a, the trial is expanding to Phase 1b/2, adding new countries.
The trial targets 391 patients with EGFR-mutant non-small cell lung cancer and lasts up to 6 years.
This disclosure involves no capital raising or share changes, so no dilution occurs.
[AI Summary]Voronoi's correction is a routine administrative step with no financial impact beyond geographic trial expansion. No direct shareholder value change, though clinical progress may boost short-term sentiment. Investors should weigh the low probability of ultimate drug approval.
KOSDAQ Filing Information
[Correction of Description] Major Management Matters Related To Investment Decision (Application For Approval Of Clinical Trial Plan Change) (Phase 1/2 Clinical Trial Of VRN110755)